Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMB NASDAQ:IMNN NYSE:NBY NASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$3.03-0.7%$3.87$2.96▼$9.84$15.67M0.51141,377 shs23,453 shsIMNNImunon$5.75+1.8%$7.32$4.83▼$41.22$14.03M2.2953,923 shs44,294 shsNBYNovaBay Pharmaceuticals$2.59-11.9%$1.16$0.46▼$4.44$15.08M0.622.55 million shs1.47 million shsSLXNSilexion Therapeutics$4.07-17.4%$9.17$3.94▼$156.60$2.98M0.04983,911 shs1.12 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics0.00%-1.94%-18.55%-38.41%-57.56%IMNNImunon0.00%-0.17%-10.16%-66.37%-63.14%NBYNovaBay Pharmaceuticals0.00%-30.56%+319.43%+331.67%+445.38%SLXNSilexion Therapeutics0.00%-43.04%-44.02%-67.70%-97.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$3.03-0.7%$3.87$2.96▼$9.84$15.67M0.51141,377 shs23,453 shsIMNNImunon$5.75+1.8%$7.32$4.83▼$41.22$14.03M2.2953,923 shs44,294 shsNBYNovaBay Pharmaceuticals$2.59-11.9%$1.16$0.46▼$4.44$15.08M0.622.55 million shs1.47 million shsSLXNSilexion Therapeutics$4.07-17.4%$9.17$3.94▼$156.60$2.98M0.04983,911 shs1.12 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics0.00%-1.94%-18.55%-38.41%-57.56%IMNNImunon0.00%-0.17%-10.16%-66.37%-63.14%NBYNovaBay Pharmaceuticals0.00%-30.56%+319.43%+331.67%+445.38%SLXNSilexion Therapeutics0.00%-43.04%-44.02%-67.70%-97.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 3.00Buy$26.50774.59% UpsideIMNNImunon 2.75Moderate Buy$232.503,943.48% UpsideNBYNovaBay Pharmaceuticals 3.00Buy$0.85-67.18% DownsideSLXNSilexion Therapeutics 3.00Buy$75.001,742.75% UpsideCurrent Analyst Ratings BreakdownLatest SLXN, CMMB, IMNN, and NBY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $25.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$2.87 per shareN/AIMNNImunon$500K28.06N/AN/A$3.82 per share1.51NBYNovaBay Pharmaceuticals$9.78M1.54N/AN/A$4.25 per share0.61SLXNSilexion TherapeuticsN/AN/AN/AN/A($37.31) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$13.94M-$2.36N/AN/AN/AN/A-94.71%-76.53%11/13/2025 (Estimated)IMNNImunon-$18.62M-$12.95N/AN/AN/AN/A-405.07%-158.41%11/6/2025 (Estimated)NBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ASLXNSilexion Therapeutics-$16.44MN/A0.00∞N/AN/AN/A-355.74%N/ALatest SLXN, CMMB, IMNN, and NBY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CMMBChemomab Therapeutics-$0.80-$0.36+$0.44-$0.09N/AN/A8/12/2025Q2 2025SLXNSilexion Therapeutics-$3.15-$4.32-$1.17-$4.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ALatest SLXN, CMMB, IMNN, and NBY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/28/2025IMNNImunonquarterly$0.158.57%8/7/20258/7/20258/21/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A7.427.42IMNNImunonN/A1.301.30NBYNovaBay PharmaceuticalsN/A1.150.91SLXNSilexion Therapeutics26.582.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%IMNNImunon4.47%NBYNovaBay Pharmaceuticals23.25%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%IMNNImunon5.96%NBYNovaBay Pharmaceuticals0.10%SLXNSilexion Therapeutics6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics205.17 million4.56 millionNot OptionableIMNNImunon302.44 million2.30 millionNot OptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableSLXNSilexion TherapeuticsN/A732,000688,000N/ASLXN, CMMB, IMNN, and NBY HeadlinesRecent News About These CompaniesSilexion Therapeutics prices 1.5M shares at $4.00 in public offeringSeptember 11, 2025 | msn.comSilexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer DataSeptember 11, 2025 | benzinga.comSilexion Therapeutics Announces Pricing of $6.0 Million Public OfferingSeptember 11, 2025 | globenewswire.comSilexion stock soars 400% after positive pancreatic cancer drug dataSeptember 11, 2025 | uk.investing.comSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationSeptember 11, 2025 | markets.businessinsider.comSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic AdministrationSeptember 11, 2025 | globenewswire.comSilexion Therapeutics selects AMS as CRO for SIL204 Phase 2/3 trialsSeptember 4, 2025 | msn.comSilexion Therapeutics Selects AMS Advanced Medical Services as CRO to Support SIL204 Phase 2/3 Clinical Trials Following Promising Preclinical ResultsSeptember 4, 2025 | quiverquant.comQSilexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204September 4, 2025 | globenewswire.comSilexion Therapeutics Corp. to Present at 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2, 2025 | quiverquant.comQSilexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSilexion Therapeutics Executes Reverse Stock SplitAugust 22, 2025 | msn.comSilexion Therapeutics Increases Authorized Share CapitalAugust 19, 2025 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deSilexion Therapeutics Corp. Reports Second Quarter 2025 Financial Results and Preclinical Advancements in RNAi Therapies for KRAS-Driven CancersAugust 12, 2025 | quiverquant.comQSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comSilexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsJuly 31, 2025 | globenewswire.comSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationJuly 31, 2025 | globenewswire.comSilexion Therapeutics Holds Annual General MeetingJuly 17, 2025 | theglobeandmail.comSilexion Therapeutics Announces 1-for-15 Reverse Share SplitJuly 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLXN, CMMB, IMNN, and NBY Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$3.03 -0.02 (-0.66%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$3.02 0.00 (-0.17%) As of 09/12/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Imunon NASDAQ:IMNN$5.75 +0.10 (+1.77%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.78 +0.03 (+0.45%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.NovaBay Pharmaceuticals NYSE:NBY$2.59 -0.35 (-11.90%) As of 09/12/2025 04:00 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Silexion Therapeutics NASDAQ:SLXN$4.07 -0.86 (-17.44%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.94 -0.13 (-3.07%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
